Announced
Completed
Financials
Sources
Tags
Minority
Friendly
Completed
Domestic
United States
Private Equity
Venture Capital
Single Bidder
biotechnology company
Private
Biotechnology
Acquisition
Synopsis
Koch Disruptive Technologies led a $215m Series B round in Immunai, a New York-based biotech company, with participation from Talos VC, 8VC, Alexandria Venture Investments, Piedmont and ICON. The new capital will be used to expand Immunai’s “drug actuary” platform for target validation and evaluation.
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.